Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Ferrer agrees to sell two of Agendia's cancer diagnostic services

Agendia : 16 July, 2008  (Company News)
Agendia and Ferrer inCode have reached an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic services.
The two services include MammaPrint, a prognostic test that uses a 70-gene signature to indicate risk of breast cancer tumor recurrence, and CupPrint, a gene expression profiling service which offers a fast and reliable method of identifying the primary tumour site in Cancer of Unknown Primary (CUP).

Under the exclusive distribution agreement, Ferrer has gained rights to sell the tests in Germany, France, Italy, and Portugal, in addition to a current agreement signed in 2007 covering Spain.

'We are confident that Ferrer inCode is the right partner for the successful expansion of MammaPrint and CupPrint into these additional European markets,' said Dr Bernhard Sixt, president and chief executive officer of Agendia. 'This agreement will allow us to increase the availability of our services to more customers in these countries, with the result being that more patients and their physicians will have access to the valuable information provided by these tests.'

MammaPrint is a clinically proven, accurate gene expression profiling test that offers healthcare professionals a personalised prognostic analysis to determine a patient's individual risk of recurrence of breast cancer.

MammaPrint, the first In Vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire market clearance from the US Food and Drug Administration (February 2007) provides information that helps physicians and patients to make more effective treatment decisions, which may include minimising the use of chemotherapy, thereby avoiding serious potential side-effects. CupPrint is an innovative diagnostic service that identifies the origin of the primary tumor in Cancer of Unknown Primary, which accounts for up to five percent of all new cancer referrals and is the fourth most common cause of cancer mortality worldwide.

'Having followed the development of MammaPrint and CupPrint, we are excited about the opportunity for Ferrer inCode to expand the commercialization of these gene expression profiling tools in these four European countries,' said Dr Carlos de Lecea, vice president, international and business development at Ferrer. 'Both tests provide valuable information that can be used to guide the therapeutic decision making process of oncologists, opening the door to a more personalised treatment for cancer patients.'

The companies are also discussing the possibility of future cooperation and expansion into other parts of the world.
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo